SEC Form 4 · accession 0001209191-16-107008
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rochelle Hanley
Officer — Chief Medical Officer
Period of report
Mar 4, 2016
Accepted (ET)
Mar 8, 2016 · 4:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.15 | Mar 4, 2016 | A | 35,250 | A | Mar 4, 2017 | Mar 4, 2026 | Common Stock | 35,250 | 35,250 | D |
Explanation of responses
- F125% of the shares subject to the option will vest on each anniversary of the grant date.